Clinical Trial Update: Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and activity of 177Lu-3BP-227 in solid tumours expressing neurotensin receptor type 1; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Cancer
• Colorectal Cancer
• Disease
• Gastric Cancer
• Pancreatic Ductal Adenocarcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Tumours

Drugs mentioned

• 177Lu-3BP-227 (177Lu-3BP-227)

Snippet

Sponsor: Ipsen | Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 | Status: TERMINATED | Results posted: 2023-12-12